Buprenorphine-based medication-assisted treatment is a long-term strategy for individuals with opioid use disorder (OUD), a condition observed at disproportionate rates among incarcerated populations. Individuals with OUD are also at higher risk of overdose and death upon community reentry, necessitating effective interventions and care modalities targeted at this high-risk population. As support for buprenorphine in correctional health care increases, so do concerns surrounding personal liability for prescribers. This article seeks to identify problematic events related to prescribing buprenorphine to incarcerated individuals, clarify medicolegal implications, and provide recommendations for safe prescribing and administration within this unique setting.
Get full access to this article
View all access options for this article.
References
1.
AlexB., WeissD. B., KabaF., RosnerZ., LeeD., LimS., VentersH., & MacDonaldR. (2017). Death after jail release: Matching to improve care delivery. Journal of Correctional Health Care, 23(1),83–87. https://doi.org/10.1177/1078345816685311
2.
BellJ. (2010). The global diversion of pharmaceutical drugs: Opiate treatment and the diversion of pharmaceutical opiates: A clinician's perspective. Addiction, 105(9),1531–1537. https://doi.org/10.1111/j.1360-0443.2010.03014.x
3.
Bi-MohammedZ., WrightN. M., HeartyP., KingN., & GavinH. (2017). Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses. Drug and Alcohol Dependence, 171,122–131. https://doi.org/10.1016/j.drugalcdep.2016.11.032
4.
BinswangerI. A., BlatchfordP. J., MuellerS. R., & SternM. F. (2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9),592–600. https://doi.org/10.7326/0003-4819-159-9-201311050-00005
BronsonJ., StroopJ., ZimmerS., & BerzofskyM. (2017). Drug use, dependence, and abuse among state prisoners and jail inmates (NCJ 250546). Bureau of Justice Statistics. https://www.bjs.gov/content/pub/pdf/dudaspji0709.pdf
7.
CisloA. M., & TrestmanR. (2013). Challenges and solutions for conducting research in correctional settings: The U.S. experience. International Journal of Law and Psychiatry, 36(3–4),304–310. https://doi.org/10.1016/j.ijlp.2013.04.002
8.
ClayE., KhemiriA., ZahV., AballéaS., RubyJ., & AscheC. V. (2014). Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence. Journal of Medical Economics, 17(9),626–636. https://doi.org/10.3111/13696998.2014.925463
9.
CollinsT. N., AvondoglioJ. B., & TerryL. M. (2017). Correctional psychopharmacology: Pitfalls, challenges, and victories of prescribing in a correctional setting. International Review of Psychiatry, 29(1),34–44. https://doi.org/10.1080/09540261.2016.1235017
CornishR., MacleodJ., StrangJ., VickermanP., & HickmanM. (2010). Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. BMJ, 341, c5475. https://doi.org/10.1136/bmj.c5475
12.
DasguptaN., BaileyE. J., CiceroT., InciardiJ., ParrinoM., RosenblumA., & DartR. C. (2010). Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Medicine, 11(7),1078–1091. https://doi.org/10.1111/j.1526-4637.2010.00877.x
13.
D'OnofrioG., ChawarskiM. C., O'ConnorP. G., PantalonM. V., BuschS. H., OwensP. H., HawkK., BernsteinS. L., & FiellinD. A. (2017). Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: Outcomes during and after intervention. Journal of General Internal Medicine, 32(6),660–666. https://doi.org/10.1007/s11606-017-3993-2
DuffyP., & BaldwinH. (2012). The nature of methadone diversion in England: A Merseyside case study. Harm Reduction Journal, 9, 3. https://doi.org/10.1186/1477-7517-9-3
GordonM. S., KinlockT. W., SchwartzR. P., FitzgeraldT. T., O'GradyK. E., & VocciF. J. (2014). A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry. Drug and Alcohol Dependence, 142,33–40. https://doi.org/10.1016/j.drugalcdep.2014.05.011
19.
GordonM. S., KinlockT. W., SchwartzR. P., O'GradyK. E., FitzgeraldT. T., & VocciF. J. (2017). A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. Drug and Alcohol Dependence, 172,34–42. https://doi.org/10.1016/j.drugalcdep.2016.11.037
Gwin MitchellS., KellyS. M., BrownB. S., Schacht ReisingerH., PetersonJ. A., RuhfA., AgarM. H., O'GradyK. E., & SchwartzR. P. (2009). Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. American Journal on Addictions, 18(5),346–355. https://doi.org/10.3109/10550490903077820
22.
HavnesI. A., ClausenT., & MiddelthonA. L. (2013). ‘Diversion’ of methadone or buprenorphine: ‘Harm’ versus ‘helping’. Harm Reduction Journal, 10, 24. https://doi.org/10.1186/1477-7517-10-24
23.
HedrichD., AlvesP., FarrellM., StöverH., MøllerL., & MayetS. (2012). The effectiveness of opioid maintenance treatment in prison settings: A systematic review. Addiction, 107(3),501–517. https://doi.org/10.1111/j.1360-0443.2011.03676.x
24.
KampmanK., & JarvisM. (2015). American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Journal of Addiction Medicine, 9(5),358–367. https://doi.org/10.1097/ADM.0000000000000166
25.
KinlockT. W., GordonM. S., & SchwartzR. P. (2011). Incarcerated populations. In P. Ruiz & E. C. Strain (Eds.), Lowinson and Ruiz's substance abuse: A comprehensive textbook (5th ed., pp. 881–891). Lippincott Williams & Wilkins.
26.
LiX., ShorterD., & KostenT. R. (2016). Buprenorphine prescribing: To expand or not to expand. Journal of Psychiatric Practice, 22(3),183–192. https://doi.org/10.1097/PRA.0000000000000154
27.
LimS., SeligsonA. L., ParvezF. M., LutherC. W., MavinkurveM. P., BinswangerI. A., & KerkerB. D. (2012). Risks of drug-related death, suicide, and homicide during the immediate post-release period among people released from New York City jails, 2001–2005. American Journal of Epidemiology, 175(6),519–526. https://doi.org/10.1093/aje/kwr327
28.
LofwallM. R., & WalshS. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. Journal of Addiction Medicine, 8(5),315–326. https://doi.org/10.1097/ADM.0000000000000045
29.
LofwallM. R., WunschM. J., & WalshS. L. (2010). Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill counts. American Journal on Addictions, 19(2),195–196. https://doi.org/10.1111/j.1521-0391.2009.00026.x
30.
MaguraS., LeeJ. D., HershbergerJ., JosephH., MarschL., ShropshireC., & RosenblumA. (2009). Buprenorphine and methadone maintenance in jail and post-release; A randomized clinical trial. Drug and Alcohol Dependence, 99(1–3),222–230. https://doi.org/10.1016/j.drugalcdep.2008.08.006
31.
MathersB. M., DegenhardtL., BucelloC., LemonJ., WiessingL., & HickmanM. (2013). Mortality among people who inject drugs: A systematic review and meta-analysis. Bulletin of the World Health Organization, 91(2),102–123. https://doi.org/10.2471/BLT.12.108282
32.
McKeeJ., PennJ. V., & KoranekA. (2014). Psychoactive medication misadventuring in correctional health care. Journal of Correctional Health Care, 20(3),249–260. https://doi.org/10.1177/1078345814532419
NSA (National Sheriffs' Association) & NCCHC (National Commission on Correctional Health Care). (2018). Jail-based medication-assisted treatment: Promising practices, guidelines, and resources for the field. https://www.ncchc.org/filebin/Resources/Jail-Based-MAT-PPG-web.pdf
36.
NunnA., ZallerN., DickmanS., TrimburC., NijhawanA., & RichJ. D. (2009). Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug and Alcohol Dependence, 105(1–2),83–88. https://doi.org/10.1016/j.drugalcdep.2009.06.015
37.
PilkintonP. D., & PilkintonJ. C. (2014). Prescribing in prison: Minimizing psychotropic drug diversion in correctional practice. Journal of Correctional Health Care, 20(2),95–104. https://doi.org/10.1177/1078345813518629
RouxP., VillesV., BryD., SpireB., FeroniI., MarcellinF., & CarrieriM. P. (2008). Buprenorphine sniffing as a response to inadequate care in substituted patients: Results from the Subazur survey in south-eastern France. Addictive Behaviors, 33(12),1625–1629. https://doi.org/10.1016/j.addbeh.2008.07.018
SordoL., BarrioG., BravoM. J., IndaveB. I., DegenhardtL., WiessingL., FerriM., & Pastor-BarriusoR. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. https://doi.org/10.1136/bmj.j1550
48.
TamburelloA., MetznerJ., FergusenE., ChampionM., FordE., GlancyG., AppelbaumK., PennJ., BurnsK., & OuradaJ. (2018). The American Academy of Psychiatry and the Law practice resource for prescribing in corrections. Journal of the American Academy of Psychiatry and the Law, 46(2),242–243. https://doi.org/10.29158/JAAPL.003762-18
VolkowN. D., FriedenT. R., HydeP. S., & ChaS. S. (2014). Medication-assisted therapies-Tackling the opioid-overdose epidemic. New England Journal of Medicine, 370(22),2063–2066. https://doi.org/10.1056/NEJMp1402780
51.
WakemanS. E., & RichJ. D. (2015). Addiction treatment within U.S. correctional facilities: Bridging the gap between current practice and evidence-based care. Journal of Addictive Diseases, 34(2–3),220–225. https://doi.org/10.1080/10550887.2015.1059217
YokellM. A., ZallerN. D., GreenT. C., & RichJ. D. (2011). Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Current Drug Abuse Reviews, 4(1),28–41. https://doi.org/10.2174/1874473711104010028
